Dinucleotide MRNA cap analogs
Novel cap analogs which are easily synthesized, resulting in high levels of capping efficiency and transcription and improved translation efficiencies are provided. Such caps are methylated at the N7 position of one or both guanosines of the dinucleotide cap as well as at the 3′ position on the ribose ring. Substituent groups on the ribose ring also result in the cap being incorporated in the forward orientation. Also provided are methods useful for preparing capped analogs and using mRNA species containing such analogs are also contemplated herein, as well as kits containing the novel cap analogs.
1. A composition comprising
wherein
A is selected from a halogen, OH, OCH 3 , H, tert-butyldimethylsilyl and 2′,3′-O-isopropylidene;
B is selected from a halogen, OH, OCH 3 , NH 2 , N 3 , NO 2 , CF 3 , CHO, S, tert-butyldimethylsilyl, LNA, and 2′,3′-O-isopropylidene;
R 1 is CH 3 or void;
R 2 is selected from OH, OCH 3 and a halogen;
n is 1, 2 or 3;
when B is OH or OCH 3 , R 1 is void and R 2 is OH, then A is neither OH nor OCH 3 ; and
wherein at least one of A or B is halogen.
2. The composition as recited in claim 1 , wherein A, B, or R 2 is fluorine.
3. The composition as recited in claim 1 attached to the 5′ end of an RNA molecule.
4. The composition as recited in claim 1 attached to the 5′ end of an RNA molecule.
5. The composition as recited in claim 2 attached to the 5′ end of an RNA molecule.
6. The composition as recited in claim 1 , wherein:
A is selected from a halogen, OH, OCH 3 , H, tert-butyldimethylsilyl and 2′,3′-O-isopropylidene;
B is selected from a halogen, OH, OCH 3 , NH 2 , N 3 , NO 2 , CHO, S, tert-butyldimethylsilyl, LNA, and 2′,3′-O-isopropylidene;
R 1 is void;
R 2 is selected from OH, OCH 3 and a halogen;
n is 1, 2 or 3;
when A is either OH or OCH 3 , then R 2 is not OH; and
wherein A, B or R 2 is halogen.
7. The composition as recited in claim 6 attached to the 5′ end of an RNA molecule.
8. The composition as recited in claim 1 , wherein:
A is selected from a halogen, OH, OCH 3 , H, -and 2′,3′-O-isopropylidene;
B is selected from CF 3 , OH, OCH 3 , NH 2 , N 3 , NO 2 , CHO, LNA, and 2′,3′-O-isopropylidene;
R 1 is CH 3 ;
R 2 is selected from OH, OCH 3 and a halogen;
n is 1, 2 or 3,
when A is OH, R 2 is not OH; and
wherein A or R 2 is halogen.
9. The composition as recited in claim 8 , wherein A or R 2 is fluorine.
10. The composition as recited in claim 8 attached to the 5′ end of an RNA molecule.
11. The composition as recited in claim 9 attached to the 5′ end of an RNA molecule.
12. A kit for capping an RNA transcript comprising:
a) an cap analog having the structure:
wherein:
A is selected from a halogen, OH, OCH 3 , H, tert-butyldimethylsilyl and 2′,3′-O-isopropylidene;
B is selected from a halogen, OH, OCH 3 , NH 2 , N 3 , NO 2 , CF 3 , CHO, S, tert-butyldimethylsilyl, LNA, and 2′,3′-O-isopropylidene;
R 1 is CH 3 or void;
R 2 is selected from OH, OCH 3 and a halogen;
n is 1, 2 or 3; and
when B is OH or OCH 3 , R 1 is void and R 2 is OH, then A is neither OH nor OCH 3 ,
wherein at least one of A or B is halogen and
b) RNA polymerase.
13. A method of synthesizing a dinucleotide cap analog comprising:
a) providing a first guanosine comprising at least one of a 2′ substituent and a 3′ substituent on the ribose ring, wherein the 2′ substituent is selected from a halogen, OCH 3 , H, tert-butyldimethylsilyl and 2′,3′-O-isopropylidene and the 3′ substituent is OH and when the 3′ substituent is selected from halogen, OH, OCH 3 , NH 2 , N 3 , NO 2 , CH 3 , CHO, S, ter-buthyldimethylsilyl, LNA, and 2′,3′-O-isopropylidene, the 2′ substituent is OH, wherein at least one of the 2′ substituent and the 3′ substituent is a halogen
b) phosphorylating the first guanosine at least twice, forming a first nucleotide,
c) methylating the first guanosine at position N-7,
d) adding a second guanosine optionally comprising a 2′ ribose ring substituent which is selected from OH, OCH 3 , and a halogen, and
e) linking said first guanosine with said second guanosine, forming a dinucleotide cap analog.
14. The kit of claim 12 further comprising nucleotides, ribonuclease inhibitor, enzyme buffer or nucleotide buffer.
15. The method of claim 13 further comprising attaching said dinucleotide cap analog to the 5′ end of an RNA molecule.